Sodium Glucose Cotransporter 2 Inhibitor and Glucagon-like Peptide 1 Receptor Agonist: New Glucose-lowering Medications and Cardiovascular Outcome
Article Sidebar
Main Article Content
Abstract
Sodium glucose co-transporter 2 inhibitor and glucagon-like peptide 1 receptor agonist are novel types of glucose-lowering drug for treatment of diabetes mellitus type 2. They are usually prescribed in form of additional therapy to the first-line drug. Clinical trials have shown benefit on cardiovascular event reduction. Dentists may encounter the patient with this new drug more prevailingly. Thus, understanding in basic of the drug is quite necessary. This article mainly performs major drug profile in terms of mechanism of action, effect on glycemic control, associated cardiovascular studies and some characteristics.
Article Details
References
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates
for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 10743-10752.
Division of Non Communicable Diseases. [URL of homepage on the Internet]. Information/ Mortality and Morbidity Rate. Nonthaburi: Division of Non Communicable Diseases; C2016 [updated 2019 Nov 18; cited 2020 Jun 29] Available from:
http://www.thaincd.com/2016/mission3
Diabetes Association of Thailand under the Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn, The Endocrine Society of Thailand, Department of Medical Services Ministry of Public Health, National Health Security Office. Clinical practice guideline for diabetes 2017. 3rd ed. Pathumthani: Romyen Media; 2017: 22.
American Diabetes Association. 2.Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S14–31.
Diabetes Association of Thailand under the Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn, The Endocrine Society of Thailand, Department of Medical Services Ministry of Public Health, National Health Security Office. Clinical practice guideline for diabetes 2017. 3rd ed. Pathumthani: Romyen Media; 2017: 39-40.
Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002; 30(3): 182–192.
Chávarry NG, Vettore MV, Sansone C. The relationship between diabetes mellitus and destructive periodontal disease: a meta-analysis. Oral Health Prev Dent 2009; 7: 107–127.
Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev 2010; (5): CD004714 .DOI: 10.1002/14651858.CD004714.pub2
Sima C, Glogauer M. Diabetes Mellitus and Periodontal Diseases. Curr Diab Rep 2013; 13: 445–452.
Diabetes Association of Thailand under the Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn, The Endocrine Society of Thailand, Department of Medical Services Ministry of Public Health, National Health Security Office. Clinical practice guideline for diabetes 2017. 3rd ed. Pathumthani: Romyen Media; 2017: 30-31.
American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of
Comorbidities: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S42.
Davies MJ, D’Alessio DA, Radkin JF, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–2498.
Sola D, Rossi L, Schianca GCP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11(4): 840–848
Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Clinical review of antidiabetic
drugs: implications for type 2 diabetes mellitus management. Pharmaceuticals 2010; 3: 3005-3020
Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic
drugs: implications for type 2 diabetes mellitus management. Front Endocrinol 2017; 8: 1-12 doi: 10.3389/fendo.2017.00006
Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide. Diabetes Metab Syndr and Obes 2019; 12: 2125–2136
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S98-S110.
Diabetes Association of Thailand under the Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn, The Endocrine Society of Thailand, Department of Medical Services Ministry of Public Health, National Health Security Office. Clinical practice guideline for diabetes 2017. 3rd ed. Pathumthani: Romyen Media; 2017: 65-74.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial Infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
Komajda M, McMurray JJV, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824–831.
Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a diabetes care editors’ expert forum. Diabetes Care 2018; 41: 14–31.
van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 2018; 41(8): 1543–1556.
Food and Drug Administration. [URL of homepage on the Internet]. National Drug Information. Nonthaburi: Food and Drug Administration; C2016 [updated 2019 Jan 10; cited 2020 Apr 30] Available from: http://ndi.fda.moph.go.th/drug_info
Bailey CJ, Iqbal N, T’Joen C, List JF. Dapagliflozin monotherapy in drug- naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012; 14(10): 951–959.
Stenlöf K, Cefalu WT, Kim K.A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15(4): 372–382.
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36(11): 3396–3404.
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsk M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: A 24-week randomized, double-blind, parallel-group trial. Diabetes Care 2017; 40(2): 201–209.
Dagogo-Jack S, Liu J, Eldor R. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 2017; 1–11.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 348-357.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. VERTIS CV investigators. cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020 383(15): 1425-1435.
Zelniker TA, Wiviott SD, Itamar R, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-2306.
U.S. Food and Drug Administration. [URL of homepage on the Internet]. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections; [updated 2015 May 14; cited 2020 Jun 30] Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-1705.
Aroda VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab 2018; Suppl 1: 22-33.
Raskin P, Mora PF. Glycaemic control with liraglutide: the phase 3 trial programme. Int J Clin Pract Suppl 2010; (167): 21-27.
Drab SR. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy. Curr Diabetes Rev 2016; 12: 403-413.
Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab 2019; 21(4): 920-929.
Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011; 45(7-8): 850-860.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-322.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-1844.
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519 -1529.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121-130.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-2257.
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239.
Cruz-Pamplona M, Jimenez-Soriano Y, Sarrión-Pérez MG. Dental considerations in patients with heart disease. J Clin Exp Dent 2011; 3(2): e97-105.
Muñoz MM, Soriano YJ, Roda RP, Sarrión G. Cardiovascular diseases in dental practice. practical considerations. Med Oral Patol Oral Cir Bucal 2008; 13(5): E296-302.
Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009; 94: 709–728.
American Diabetes Association, workup on hypoglycemia. Defining and Reporting Hypoglycemia in Diabetes: A Report From the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28(5): 1245-1249.
Franki L. [URL of homepage on the Internet]. FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery; C1994-2020 [updated 2020 Mar 18; cited 2020 Jun 30] Available from https://www.medscape.com/viewarticle/927047
Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014; 53(4): 295-304.
Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother 2012; 46(5): 710-717.